Suppr超能文献

减毒和复制型痘苗病毒株 M65 和 M101,具有不同的生物学和免疫原性,可作为针对病原体的潜在候选疫苗。

Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens.

机构信息

Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain.

出版信息

J Virol. 2013 Jun;87(12):6955-74. doi: 10.1128/JVI.03013-12. Epub 2013 Apr 17.

Abstract

Replication-competent poxvirus vectors with an attenuation phenotype and with a high immunogenic capacity of the foreign expressed antigen are being pursued as novel vaccine vectors against different pathogens. In this investigation, we have examined the replication and immunogenic characteristics of two vaccinia virus (VACV) mutants, M65 and M101. These mutants were generated after 65 and 101 serial passages of persistently infected Friend erythroleukemia (FEL) cells. In cultured cells of different origins, the mutants are replication competent and have growth kinetics similar to or slightly reduced in comparison with those of the parental Western Reserve (WR) virus strain. In normal and immune-suppressed infected mice, the mutants showed different levels of attenuation and pathogenicity in comparison with WR and modified vaccinia Ankara (MVA) strains. Wide genome analysis after deep sequencing revealed selected genomic deletions and mutations in a number of viral open reading frames (ORFs). Mice immunized in a DNA prime/mutant boost regimen with viral vectors expressing the LACK (Leishmania homologue for receptors of activated C kinase) antigen of Leishmania infantum showed protection or a delay in the onset of cutaneous leishmaniasis. Protection was similar to that triggered by MVA-LACK. In immunized mice, both polyfunctional CD4(+) and CD8(+) T cells with an effector memory phenotype were activated by the two mutants, but the DNA-LACK/M65-LACK protocol preferentially induced CD4(+) whereas DNA-LACK/M101-LACK preferentially induced CD8(+) T cell responses. Altogether, our findings showed the adaptive changes of the WR genome during long-term virus-host cell interaction and how the replication competency of M65 and M101 mutants confers distinct biological properties and immunogenicity in mice compared to those of the MVA strain. These mutants could have applicability for understanding VACV biology and as potential vaccine vectors against pathogens and tumors.

摘要

复制型痘病毒载体具有衰减表型和高免疫原性,是针对不同病原体的新型疫苗载体。在这项研究中,我们研究了两种牛痘病毒(VACV)突变株 M65 和 M101 的复制和免疫特性。这些突变株是在持续感染 Friend 红白血病(FEL)细胞的 65 和 101 次连续传代后产生的。在不同来源的培养细胞中,这些突变株具有复制能力,其生长动力学与亲本西部储备(WR)病毒株相似或略有降低。在正常和免疫抑制感染的小鼠中,与 WR 和改良痘苗病毒安卡拉(MVA)株相比,这些突变株的衰减和致病性水平不同。深度测序后的全基因组分析显示,在许多病毒开放阅读框(ORF)中存在选择的基因组缺失和突变。用表达利什曼原虫激活 C 激酶受体同源物(LACK)抗原的病毒载体进行 DNA 初免/突变体加强免疫的小鼠表现出对皮肤利什曼病的保护或发病延迟。保护作用与 MVA-LACK 触发的保护作用相似。在免疫小鼠中,两种突变体都能激活具有效应记忆表型的多功能 CD4(+)和 CD8(+)T 细胞,但 DNA-LACK/M65-LACK 方案优先诱导 CD4(+),而 DNA-LACK/M101-LACK 则优先诱导 CD8(+)T 细胞反应。总之,我们的研究结果表明,WR 基因组在长期病毒-宿主细胞相互作用过程中发生了适应性变化,以及 M65 和 M101 突变株的复制能力如何赋予其与 MVA 株相比在小鼠中具有不同的生物学特性和免疫原性。这些突变株可能适用于了解 VACV 生物学,以及作为针对病原体和肿瘤的潜在疫苗载体。

相似文献

引用本文的文献

7
The evolution of poxvirus vaccines.痘病毒疫苗的演变
Viruses. 2015 Apr 7;7(4):1726-803. doi: 10.3390/v7041726.
8
Enhancing poxvirus vectors vaccine immunogenicity.增强痘病毒载体疫苗的免疫原性。
Hum Vaccin Immunother. 2014;10(8):2235-44. doi: 10.4161/hv.28974.

本文引用的文献

1
Poxvirus vectors as HIV/AIDS vaccines in humans.痘病毒载体作为人类艾滋病疫苗。
Hum Vaccin Immunother. 2012 Sep;8(9):1192-207. doi: 10.4161/hv.20778. Epub 2012 Aug 21.
4
Improved NYVAC-based vaccine vectors.改良基于 NYVAC 的疫苗载体。
PLoS One. 2011;6(11):e25674. doi: 10.1371/journal.pone.0025674. Epub 2011 Nov 9.
7
CD8+ T effector memory cells protect against liver-stage malaria.CD8+ T 效应记忆细胞可预防肝脏期疟疾。
J Immunol. 2011 Aug 1;187(3):1347-57. doi: 10.4049/jimmunol.1100302. Epub 2011 Jun 29.
10
Poxvirus vector-based HIV vaccines.痘病毒载体 HIV 疫苗。
Curr Opin HIV AIDS. 2010 Sep;5(5):391-6. doi: 10.1097/COH.0b013e32833d1e87.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验